Tuesday, October 16, 2007 12:11:18 AM
My take is similar to your take docbanker but I am a bit more enthusiastic about the press release than you are.
The fact that QOL is out is a huge plus for RPRX. However the fact that they did not specify yet what the specific endocrine endpoints are makes me a bit confused. Moreover, I am not clear as to what impact these endocrine endpoints would have on approval. For instance, what if the trial shows statistically significant results regarding Testesterone but not with respect to the endocrine endpoints? Does that mean we do not get approval or does it simply mean that we get approval but for a narrower indiction as far as labeling is concerned...
As to whether or not they will have to run another phase II trial before proceeding with their phase III, that is a big mistery at this point and the press release can be interpreted both ways. Perhaps they simply want to suggest the endocrine endpoints after some thought or perhaps the FDA wants some confirmation based on a quick phase II trial, I am not clear which is the case.
Overall however, this is a huge positive for RPRX and should reflect in the behavior of the stock going forward. Perhaps the stock will not react instantaneously to the news because of the possible need for an extra phase II, but when you take the larger market potential into account as well as the lack of QOL endpoints, it will be clear to most with time that RPRX is getting ready to partner Androxal and the stock should move well past $15 within a short period of time. In fact, given the low float, I would not be surprised to see us cross $20 before year-end, especially if a few analysts jump on this badwagon...
Tomorrow should make for some interesting trading. Currently, my plan is to be a buyer for any price under $12 but I will wait to see the market reaction in the morning before jumping in because I am already very long RPRX... However, the one thing I will certainly do tomorrow is to unload the Puts that I had bought for insurance protection because I expect those to eventually expire worthless...
The fact that QOL is out is a huge plus for RPRX. However the fact that they did not specify yet what the specific endocrine endpoints are makes me a bit confused. Moreover, I am not clear as to what impact these endocrine endpoints would have on approval. For instance, what if the trial shows statistically significant results regarding Testesterone but not with respect to the endocrine endpoints? Does that mean we do not get approval or does it simply mean that we get approval but for a narrower indiction as far as labeling is concerned...
As to whether or not they will have to run another phase II trial before proceeding with their phase III, that is a big mistery at this point and the press release can be interpreted both ways. Perhaps they simply want to suggest the endocrine endpoints after some thought or perhaps the FDA wants some confirmation based on a quick phase II trial, I am not clear which is the case.
Overall however, this is a huge positive for RPRX and should reflect in the behavior of the stock going forward. Perhaps the stock will not react instantaneously to the news because of the possible need for an extra phase II, but when you take the larger market potential into account as well as the lack of QOL endpoints, it will be clear to most with time that RPRX is getting ready to partner Androxal and the stock should move well past $15 within a short period of time. In fact, given the low float, I would not be surprised to see us cross $20 before year-end, especially if a few analysts jump on this badwagon...
Tomorrow should make for some interesting trading. Currently, my plan is to be a buyer for any price under $12 but I will wait to see the market reaction in the morning before jumping in because I am already very long RPRX... However, the one thing I will certainly do tomorrow is to unload the Puts that I had bought for insurance protection because I expect those to eventually expire worthless...
Recent RPRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 01:20:12 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 08:23:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2026 08:38:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2026 09:22:49 PM
- Form 13F-NT - Quarterly report filed by institutional managers, Notice • Edgar (US Regulatory) • 05/14/2026 06:29:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:14:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:12:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:10:50 PM
- Royalty Pharma to present at upcoming investor conferences • GlobeNewswire Inc. • 05/07/2026 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 01:04:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:31:54 AM
- Royalty Pharma reports first quarter 2026 results • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/30/2026 09:54:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/28/2026 09:00:16 PM
- Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation • GlobeNewswire Inc. • 04/21/2026 05:00:00 PM
- Royalty Pharma Declares Second Quarter 2026 Dividend • GlobeNewswire Inc. • 04/17/2026 12:30:00 PM
- Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 • GlobeNewswire Inc. • 04/15/2026 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/13/2026 01:53:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/10/2026 08:11:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 08:10:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:58:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 08:55:58 PM
- Royalty Pharma signs $500M co-development agreement with J&J • IH Market News • 03/30/2026 12:28:19 PM
